Like previous years, the EAP Congress and MasterCourse 2017 was again a success! More than 700 paediatricians from 80 countries visited Ljubljana (Slovenia) to exchange ideas and information, and to meet colleagues from all over the world.
This year, the MasterCourse focussed on Paediatric Infections and included a diverse range of topics like the evaluation and treatment of infections in migrant children in Europe, discussion of recent guidelines of the European Society of Paediatric Infectious Diseases (like paediatric bone and joint infections) and presentation of European consensus guidelines for congenital CMV infection.
The EAP Congress provided the most up-to-date and state-of-the-art information on the latest developments in research and clinical practice in the fundamental areas of Paediatrics. In addition, interesting discussions emerged, for example on how paediatricians can improve vaccine uptake across Europe and tackle health inequalities. The editor-in-chief of the European Journal of Paediatrics, EAP’s official journal, was present during the meet-the-editor session.
The EAP is looking forward to meeting you again during next year’s EAPS Congress in Paris!
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
